Compare BSX & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSX | ARGX |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0B | 55.1B |
| IPO Year | 2010 | 2017 |
| Metric | BSX | ARGX |
|---|---|---|
| Price | $43.68 | $945.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 31 | 25 |
| Target Price | $49.60 | ★ $1,150.61 |
| AVG Volume (30 Days) | ★ 18.1M | 377.7K |
| Earning Date | 10-28-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.20 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $9,076,000,000.00 | N/A |
| Revenue This Year | $4.46 | $53.06 |
| Revenue Next Year | N/A | $23.03 |
| P/E Ratio | ★ $22.42 | $33.69 |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $39.57 | $661.85 |
| 52 Week High | $101.91 | $1,072.75 |
| Indicator | BSX | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 55.50 |
| Support Level | $42.31 | $934.19 |
| Resistance Level | $46.31 | $1,072.75 |
| Average True Range (ATR) | 1.61 | 26.19 |
| MACD | -0.10 | 4.75 |
| Stochastic Oscillator | 25.83 | 64.22 |
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.